Valence ロゴ
人気
ログイン
Loading data for GALDY — first visit, this takes a few seconds.

ウォッチリストに追加

Galderma Group AG

OTC Markets OTCPK: GALDY · リアルタイム株価 · USD
42.45
-0.31 (-0.72%)
終値時点： Aug 24, 2026, 7:58 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Galderma Group AG（GALDY）の株価・分析・データ

-0.72%

データがありません

買気配42.43
時価総額49.49B
売上高（TTM）5.92B
純利益（TTM）863M
-0.10
0.73
58.15
6.71
PBR（TTM）6.02
PSR（TTM）8.36
決算発表日n/a
売気配42.52
出来高4,548
平均出来高（20日）127,063
始値42.59
前日終値42.76
当日レンジ42.40 - 42.64
52週レンジ33.13 - 46.31
アナリストn/a
目標株価n/a
配当$0.09 (0.21%)
権利落ち日2026年4月27日

GALDYについて

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix...

[続きを読む]
業種 Drug Manufacturers - Specialty & Generic
セクター Healthcare
IPO日 Aug 15, 2024
従業員数 7,676
上場取引所 OTC Markets OTCPK
ティッカー GALDY
ウェブサイト https://www.galderma.com
企業情報の全文

業績

2025年のGaldermaの売上高は5.24Bで、前年の4.44Bから18.04%の増加でした。 利益は613Mで、165.37%の増加でした。

財務諸表
news image

1か月前 · Investing.com

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth f...

news image

1か月前 · GuruFocus.com

Galderma Group AG (GDERF) Half Year 2026 Earnings Call Highlights: Record Sales and Strategic ...

Galderma Group AG (GDERF) reports robust sales growth and strategic advancements, while navigating regulatory and market challenges.

news image

1か月前 · The Wall Street Journal

Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S.

Shares dropped after the skincare group failed to secure approval for its latest antiwrinkle treatment, a potential rival to AbbVie’s Botox.

news image

1か月前 · Investing.com

Galderma falls after FDA issues second setback for Botox rival

Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment Relabotulinumto...

news image

2か月前 · Zacks

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

2ページ中1ページ